Issue 4/2013
Content (16 Articles)
Management of Double-Refractory Multiple Myeloma
Jason P. Meadows, Tomer M. Mark
Incorporating Novel Agents in the Management of Elderly Myeloma Patients
Tommasina Guglielmelli, Antonio Palumbo
New Approaches to Smoldering Myeloma
María-Victoria Mateos, Jesús F. San Miguel
Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy
Jordan Schecter, Suzanne Lentzsch
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?
Sergio Giralt, Guenther Koehne
New Insights and Modern Treatment of AL Amyloidosis
Chakra P. Chaulagain, Raymond L. Comenzo
Genetic Basis of MPN: Beyond JAK2-V617F
Nicole C. C. Them, Robert Kralovics
Are MPNs Vascular Diseases?
Guido Finazzi, Valerio De Stefano, Tiziano Barbui
Preclinical Models for Drug Selection in Myeloproliferative Neoplasms
Niccolò Bartalucci, Costanza Bogani, Alessandro M. Vannucchi
The New Landscape of Therapy for Myelofibrosis
Krisstina Gowin, Robyn Emanuel, Holly Geyer, Ruben A. Mesa
WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update
Hans Michael Kvasnicka
Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons
Moosa Qureshi, Claire Harrison
There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes
Amer M. Zeidan, Rami S. Komrokji
Standardizing the Initial Evaluation for Myelodysplastic Syndromes
Danielle Marshall, Gail J. Roboz
Febrile Neutropenia in Hematologic Malignancies
Michael K. Keng, Mikkael A. Sekeres
When to Transplant MDS, and What to Do When Transplant Fails
Katja Sockel, Uwe Platzbecker